Saturday 17 October 2026
Export QTRX’s income statement to Excel — free account
Quanterix Corporation
QTRX Healthcare Medical Devices
Quanterix Corporation’s revenue for fiscal 2025 (year ended December 2025) was $138.9 million, up 1.07% from fiscal 2024. In the quarter to June 2026, revenue grew 34.4%, EPS fell 35.1% and free cash flow grew 18.9%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
2.87
0.20
−6.51%
Follow QTRX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
1.33 | 1.14 | 1.95 | 1.92 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(39.80) | (9.13) | (16.49) | (6.06) | |
P/B ratio |
0.86 | 0.59 | 0.92 | 0.80 | |
Price to Tangible BV |
1.55 | 1.13 | 1.97 | 1.60 | |
EV/Sales |
0.73 | 0.47 | 1.12 | 0.90 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.39) | (0.84) | (2.01) | (1.81) | |
EV/FCF |
(1.38) | (0.83) | (1.95) | (1.73) | |
Quick Ratio |
2.30 | 2.53 | 1.98 | 2.17 | |
Current Ratio |
3.40 | 3.72 | 2.84 | 3.02 | |
Net Debt/EBITDA |
2.20 | 2.84 | 9.21 | 4.38 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.11% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.44 | 0.38 | 0.34 | 0.30 | |
Operating CF/Net income |
0.10 | 1.03 | 0.71 | 1.23 | |
Capex/Depreciation |
(0.01) | (0.01) | 0.01 | (0.10) | |
Research and Development Expense of Revenue |
23.77% | 20.11% | 20.06% | 19.91% | |
Selling, General and Administrative Expense of Revenue |
83.12% | 81.75% | 85.34% | 97.09% | |
Intangible Assets out of Total Assets |
0.33 | 0.37 | 0.38 | 0.36 | |
Share Based Compensation of Revenue |
12.80% | 12.43% | 10.07% | 13.59% | |
Graham Net Nets |
0.44 | 0.61 | 0.33 | 0.41 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(60.88%) | (67.05%) | (39.62%) | (42.91%) | |
Free Cash Flow Yield |
(40.09%) | (50.13%) | (29.44%) | (27.27%) | |
Revenue per Share |
0.70 | 0.78 | 1.03 | 0.87 | |
Operating CF per Share |
(0.11) | (0.39) | (0.39) | (0.90) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.01) | |
Free Cash Flow per Share |
(0.11) | (0.39) | (0.38) | (0.91) | |
Cash per Share |
1.98 | 2.11 | 2.77 | 2.93 | |
Shareholders Equity per Share |
5.03 | 6.01 | 6.94 | 6.83 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.03 | 6.01 | 6.94 | 6.83 | |
Free Cash Flow |
(5.21) | (18.19) | (16.35) | (41.93) | |
Working Capital |
120.68 | 135.82 | 137.50 | 155.93 | |
Capital Expenditures |
(0.10) | (0.09) | 0.10 | (0.68) | |
Net Current Asset Value |
88.64 | 101.19 | 89.22 | 103.67 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
22.95 | 27.52 | 31.06 | 32.06 | |
Average Payables |
9.01 | 7.69 | 10.26 | 8.51 | |
Average Inventory |
38.87 | 40.99 | 43.77 | 43.96 | |
Average Assets |
347.62 | 381.59 | 412.65 | 427.58 | |
Average Common Equity |
264.84 | 299.27 | 312.88 | 326.71 |
Columns are period end dates